eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2021
vol. 13
 
Share:
Share:
more
 
 
abstract:
Case report

Adjuvant high-dose-rate interstitial brachytherapy for malignant peripheral nerve sheath tumor of the foot: a case report

Andrea Vavassori
1
,
Elisabetta Pennacchioli
2
,
Matteo Augugliaro
1
,
Stefano Durante
1
,
Samantha Dicuonzo
1
,
Gian Marco Orsolini
2
,
Pierpaolo Prestianni
2
,
Raffaella Cambria
3
,
Stefania Comi
3
,
Giovanni Mazzarol
4
,
Federica Cattani
3
,
Roberta Lazzari
1
,
Roberto Orecchia
5
,
Barbara Alicja Jereczek-Fossa
1, 6

1.
Department of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy
2.
Division of Sarcoma and Melanoma, IEO European Institute of Oncology IRCCS, Milan, Italy
3.
Unit of Medical Physics, IEO European Institute of Oncology IRCCS, Milan, Italy
4.
Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy
5.
Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy
6.
University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy
J Contemp Brachytherapy 2021; 13, 3: 338–346
Online publish date: 2021/05/18
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Soft tissue sarcomas of the foot are extremely rare and can therefore be misdiagnosed as benign diseases, and be prematurely removed with an unplanned excision. The standard treatment is a wide local excision with an addition of radiotherapy as an alternative to a radical resection (e.g., below-knee or foot amputation). We report on a patient with primary malignant peripheral nerve sheath tumor in the foot plantar soft tissue, who had no evidence of the disease and no severe late toxicity higher than grade 2, 40 months after receiving amputation of toes and adjuvant interstitial high-dose-rate brachytherapy (HDR-BT). To the best of our knowledge, only a few cases were treated with HDR-BT with this scenario. From our findings, HDR-BT could be a safe and quick treatment option for these types of lesions.
keywords:

interstitial HDR brachytherapy, foot soft tissue sarcoma, MPNST, lower extremity

 
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe